<DOC>
	<DOCNO>NCT00697749</DOCNO>
	<brief_summary>This study compare immunogenicity safety novel adjuvanted HBV vaccine Engerix™-B administer subject positively identify HLA-DQ2 genotype</brief_summary>
	<brief_title>Immunogenicity Safety Novel Adjuvanted HBV Vaccine Healthy Volunteers Positive HLA-DQ2 Genotype</brief_title>
	<detailed_description>At time conduct study , sponsor GlaxoSmithKline know former name SmithKline Beecham</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male female ≥ 15 year age time first vaccination . Free obvious health problem establish medical history clinical examination enter study . Written inform consent obtain subject/ parent guardian subject . Known seronegative antiHBsantibodies , antiHBcantibodies and/or HBsAg . Positive HLADQ2 genotype determine previous seroHBV069 prevalence study . If subject female , must nonchildbearing potential , , childbearing potential , must abstinent use adequate contraceptive precaution one month prior enrollment two month last vaccination Use investigational nonregistered drug vaccine study vaccine ( ) study period within 30 day precede first dose study vaccine . Planned administration/ administration vaccine foreseen study protocol period start 30 day dose vaccine end 30 day . Previous vaccination hepatitis B . History nonresponse previous hepatitis B vaccination . Known exposure hepatitis B within 6 week . History hepatitis B infection . Confirmed human immunodeficiency virus ( HIV ) infection . A family history congenital hereditary immunodeficiency . History allergic disease reaction likely exacerbate component vaccine . Acute disease time enrollment . Hepatomegaly , right upper quadrant abdominal pain tenderness . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration/ administration study period . Pregnant lactate female</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Recombinant hepatitis B vaccine</keyword>
	<keyword>Adjuvanted hepatitis B vaccine</keyword>
	<keyword>Hepatitis B</keyword>
</DOC>